Reimbursed Care Access in Lao People's Democratic Republic

Currently classified as a strictly controlled psychotropic substance under Lao PDR drug-control regulations; there is no authorized medical or reimbursed access outside of approved research. Enforcement is uneven in some tourist areas, but the statutory framework treats psilocybin (magic mushrooms) as illegal and subject to severe criminal penalties for trafficking. # #

Currently classified as a strictly controlled substance under the Lao narcotics/psychotropic framework; there is no authorized medical or reimbursed access for MDMA-assisted therapy outside of approved clinical research (and to date no public record of an approved clinical program in Lao PDR). Possession, manufacture or trafficking are criminal offences under national law and subject to severe penalties. #

Esketamine (the intranasal antidepressant product marketed in some countries) is not listed as an authorized, reimbursed medicine in Lao PDR and there is no public record of regulatory marketing authorization or routine clinical/reimbursed use. All importation, sale or use of narcotic/psychotropic medicines requires permits from the Ministry of Health under Decision No. 08/MoH; novel centrally acting antidepressant products containing controlled substances would therefore require explicit MOH approval and registration and are not part of the standard National Health Insurance benefit package as described by Lao health financing guidance. # #

Ketamine in Lao PDR is regulated under the Ministry of Health lists and import/use requires formal permits from the Ministry (Food and Drug Department) per Decision No. 08/MoH; the regulation establishes lists and an annual-permit/import plan requirement for narcotics/psychotropic substances. As a result, ketamine can be present in the country for legitimate medical uses (e.g., anesthesia in hospitals) but is tightly controlled, and routine coverage/reimbursement for ketamine when used off-label for psychiatric indications (such as depression infusions) is not an established pathway under the National Health Insurance (NHI) framework. Public health financing in Laos is managed under the NHI scheme (National Health Insurance Bureau / Ministry of Health) which defines covered services and reimbursable medicines; there is no public documentation that ketamine is reimbursed for psychiatric/psychedelic-assisted care or that esketamine nasal spray has regulatory approval or inclusion in NHI benefits. Clinical use of ketamine in hospitals therefore depends on facility licensure, MOH permits for importation/supply, and local hospital procurement practices rather than a national reimbursed mental-health indication. Enforcement and interdiction against unauthorised distribution are active (large seizures of ketamine have been reported by Lao authorities), underscoring regulatory control over supply. # # #

Currently classified as a strictly controlled substance under Lao narcotics/psychotropic regulations with no authorized medical use or reimbursement outside of approved clinical research. There is no public record of registered DMT-based medical programs or regulatory approvals in Lao PDR. #

Currently classified as a strictly controlled substance under national drug scheduling laws with no authorized medical use or reimbursement in Lao PDR outside of approved research. There is no evidence of legal clinical programs using 5‑MeO‑DMT in the country. #

Currently classified as a strictly controlled substance under Lao drug-control regulations, with no authorized medical use or reimbursement; ibogaine-assisted treatment is not recognized or licensed in Lao PDR outside of approved clinical research. #

The active constituents of ayahuasca (DMT and related compounds) are controlled under Lao narcotics/psychotropic substance regulations; there is no legally authorized clinical or reimbursed use of ayahuasca ceremonies or preparations in the Lao health system. Use outside approved research would be subject to criminal control measures. #

Classified as a controlled psychotropic/narcotic substance under Lao regulation with no authorized medical/reimbursed use outside approved research. There is no national framework permitting mescaline-containing cactus preparations for medical therapy in Lao PDR. #

2C‑series phenethylamines (commonly referred to as '2C‑X' compounds) are controlled under psychotropic substance controls in Lao PDR and have no authorized medical or reimbursed use; possession, manufacture or trafficking are criminal offences except where permitted under formal MOH-authorized research. #